Abstract
Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. One objective response was seen for an overall response rate of 5% (95% confidence interval 0-24%). Toxicities of grade > or = 3 were primarily hematologic and seen in 13/21 patients. Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Anthraquinones / adverse effects
-
Anthraquinones / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Stomach Neoplasms / drug therapy*
Substances
-
Anthraquinones
-
Antineoplastic Agents
-
Pyrazoles
-
piroxantrone